AI leaders call for tougher protections against AI-aided bioweapons

Competitors in AI are finding common ground on biosecurity. Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman signed an open letter pushing Congress to close what they're calling a dangerous gap in bioweapon prevention.

The specific ask is straightforward: require companies that sell synthetic DNA and RNA to screen customer orders. Right now, you can order genetic material online and have it shipped to a lab without much oversight. The concern is that AI models could help someone design dangerous biological sequences, then order the materials to build them.

This isn't about what AI models can do today as much as what they might enable soon. As these systems get better at understanding biology and chemistry, the barrier to engineering a pathogen drops. The tech leaders see this coming and want guardrails in place before it becomes a real threat.

For anyone building with AI, this is a reminder that capability comes with responsibility. The industry is starting to self-regulate on the scariest use cases, which could mean more restrictions on what models can help you do in sensitive domains like synthetic biology.

The fact that rivals are aligning on this suggests they're genuinely worried. When companies that normally compete on safety credentials agree on policy, it's worth paying attention to what they're trying to prevent.